Product logins

Find logins to all Clarivate products below.


Chronic Sinusitis | Treatment Algorithms: Claims Data Analysis | US | 2020

Chronic sinusitis is prolonged inflammation of the paranasal sinuses that persists for more than 12 weeks despite treatment. Intranasal corticosteroids are typically used for treatment, followed by antibiotics or allergy medications, such as antihistamines, decongestants, leukotriene inhibitors, and anti-inflammatory agents. Although chronic sinusitis is one of the more-prevalent chronic illnesses in the United States, not many treatment options are available. Because no antibiotics are currently approved by the FDA to treat chronic sinusitis, otolaryngologists often prescribe antibiotics off-label based primarily on historical practice.

The report answers key questions including:

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed chronic sinusitis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed chronic sinusitis patients?
  • How has the amoxicillin-clavulanate combination been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of chronic sinusitis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of chronic sinusitis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Treatment Algorithms Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound…